Clinical Trial Update: Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children [Phase 1]

View source ↗

Summary

Phase 1 safety and efficacy study of Besivance (besifloxacin) for treating congenital nasolacrimal duct obstruction in children; the trial is completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Nasolacrimal Duct Obstruction

Drugs mentioned

• BESIVANCE (besifloxacin)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Congenital Nasolacrimal Duct Obstruction | Phase 1 | Status: COMPLETED | Results posted: 2016-06-09